Shares of bluebird bio climbed in trading after the company announced on March 10 that analyses demonstrate the lentiviral vector BB305 was unlikely to be the cause of acute myeloid leukemia (AML) reported in an early-stage clinical study of LentiGlobin for sickle cell disease.
Neoleukin was benched by the FDA with a clinical hold for the biopharma company’s lead cancer immunotherapy candidate.
Cellectis announced that the U.S. Food and Drug Administration placed a clinical hold on the company’s MELANI-01 trial of UCARTCS1A for relapsed or refractory multiple myeloma (MM).
Shares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.
Bayer halted trials testing the experimental uterine fibroids treatment vilaprisan, which the company previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects.
Affimed N.V. put on hold the testing of the drug developer’s experimental cancer drug following the death of a patient and two life-threatening events.
Seattle Genetics said four people died in trials testing its experimental cancer drug, prompting the U.S. FDA to impose a clinical hold on several early-stage studies.
Juno Therapeutics Inc. said two more patients had died after suffering brain swelling during a trial of its experimental genetically engineered leukemia drug.
Shares of Arrowhead Pharmaceuticals were down after the company’s experimental hepatitis B drug, ARC-520, was placed on clinical hold by the U.S. FDA.
AstraZeneca’s high hopes for cancer immunotherapy were dented as the recruitment of new patients with head and neck cancer into two clinical studies was put on hold, following instances of bleeding.